Literature DB >> 6970527

Susceptibility to atherosclerosis in aortas and coronary arteries of swine with von Willebrand's disease.

T R Griggs, R L Reddick, D Sultzer, K M Brinkhous.   

Abstract

The development of coronary and aortic atherosclerosis was determined after balloon catheter injury of coronary arteries and administration of an atherogenic diet in normal pigs and pigs that were homozygous and heterozygous for von Willebrand's disease. Coronary atherosclerosis developed to a similar degree in all three phenotypic groups. The mean intimal thickness at the site of maximal thickness in ballooned vessels was .51 mm in the normal pigs, .67 mm in carrier pigs, and .55 mm in bleeder pigs. The intimal thickness of non-ballooned vessels was .28 mm in normal pigs, .28 mm in carrier pigs, and .35 mm in bleeder pigs. Fibrous lesions of atherosclerosis covered an average of 3.88% of the aorta in normal pigs, 2.83% in carrier pigs, and 2.37% in bleeder pigs. The difference between the aortic lesions of normal animals and bleeders was significant (P less than .05). Absence of von Willebrand factor was associated with limited resistance to atherosclerosis in the aortas of experimental pigs but did not affect the development of atherosclerosis in either ballooned or nonballooned coronary arteries. These findings suggest, first, that von Willebrand factor function is not essential to the development of the atherosclerotic lesion in this model and, second, that the role of the von Willebrand factor in the development of atherosclerosis is complicated and appears to involve interaction with variables not yet defined.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6970527      PMCID: PMC1903684     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  17 in total

1.  Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure.

Authors:  R D LANGDELL; R H WAGNER; K M BRINKHOUS
Journal:  J Lab Clin Med       Date:  1953-04

2.  Advanced coronary atherosclerosis in swine produced by combination of balloon-catheter injury and cholesterol feeding.

Authors:  W M Lee; K T Lee
Journal:  Exp Mol Pathol       Date:  1975-12       Impact factor: 3.362

3.  Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor.

Authors:  J P Allain; H A Cooper; R H Wagner; K M Brinkhous
Journal:  J Lab Clin Med       Date:  1975-02

4.  Thromboatherosclerosis in normolipemic rabbits. A result of continued endothelial damage.

Authors:  S Moore
Journal:  Lab Invest       Date:  1973-11       Impact factor: 5.662

5.  Repair in arterial tissue. Morphological and biochemical changes in rabbit aorta after a single dilatation injury.

Authors:  P Helin; I Lorenzen; C Garbarsch; M E Matthiessen
Journal:  Circ Res       Date:  1971-11       Impact factor: 17.367

6.  Radiographic visualization of coronary arteries in postmortem hearts: a simple technic.

Authors:  C O Suberman; R I Suberman; F G Dalldorf; O F Gabriele
Journal:  Am J Clin Pathol       Date:  1970-02       Impact factor: 2.493

7.  A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro.

Authors:  R Ross; J Glomset; B Kariya; L Harker
Journal:  Proc Natl Acad Sci U S A       Date:  1974-04       Impact factor: 11.205

8.  Effect of cholesterol on production of thromboxane b2 by platelets in vitro.

Authors:  M J Stuart; J M Gerrard; J G White
Journal:  N Engl J Med       Date:  1980-01-03       Impact factor: 91.245

9.  Von Willebrand factor: gene dosage relationships and transfusion response in bleeder swine--a new bioassay.

Authors:  T R Griggs; W P Webster; H A Cooper; R H Wagner; K M Brinkhous
Journal:  Proc Natl Acad Sci U S A       Date:  1974-05       Impact factor: 11.205

10.  Experimental arteriosclerosis. I. Fibrous plaque formation in primates, an electron microscope study.

Authors:  M B Stemerman; R Ross
Journal:  J Exp Med       Date:  1972-10-01       Impact factor: 14.307

View more
  7 in total

1.  The Cardioprotective Potential of von Willebrand Disease in Ischemic Heart Disease.

Authors:  Nawfal Mihyawi; Muhammad Ajmal; Ayman R Fath; Bikash Bhattarai; Beeletsega Yeneneh
Journal:  Tex Heart Inst J       Date:  2022-07-01

2.  Platelet adhesion to damaged coronary arteries: Comparison in normal and von Willebrand disease swine.

Authors:  R L Reddick; T R Griggs; M A Lamb; K M Brinkhous
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

3.  Porcine von Willebrand disease and atherosclerosis. Influence of polymorphism in apolipoprotein B100 genotype.

Authors:  T C Nichols; D A Bellinger; K E Davis; G G Koch; R L Reddick; M S Read; J Rapacz; J Hasler-Rapacz; K M Brinkhous; T R Griggs
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

4.  Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, thrombosis, and atherosclerosis studies.

Authors:  Timothy C Nichols; Dwight A Bellinger; Elizabeth P Merricks; Robin A Raymer; Mark T Kloos; Natalie Defriess; Margaret V Ragni; Thomas R Griggs
Journal:  Thrombosis       Date:  2011-02-07

5.  BLOC-2 subunit HPS6 deficiency affects the tubulation and secretion of von Willebrand factor from mouse endothelial cells.

Authors:  Jing Ma; Zhe Zhang; Lin Yang; Janos Kriston-Vizi; Daniel F Cutler; Wei Li
Journal:  J Genet Genomics       Date:  2016-10-21       Impact factor: 4.275

6.  MicroRNA-374b induces endothelial-to-mesenchymal transition and early lesion formation through the inhibition of MAPK7 signaling.

Authors:  Byambasuren Vanchin; Emma Offringa; Julian Friedrich; Marja Gl Brinker; Bianca Kiers; Alexandre C Pereira; Martin C Harmsen; Jan-Renier Aj Moonen; Guido Krenning
Journal:  J Pathol       Date:  2019-01-16       Impact factor: 7.996

7.  Animal models of coronary heart disease.

Authors:  Jiawei Liao; Wei Huang; George Liu
Journal:  J Biomed Res       Date:  2015-08-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.